Marker’s lead product candidate, a multi-antigen targeted T-cell treatment for patients with AML, is currently being evaluated in a Phase 2 multicenter trial in patients with AML after a stem cell transplant.

Unlike other therapies, Marker’s approach has the potential to target multiple cancer cells within a tumor, which may reduce the risk of tumor evasion. Data from a Phase 1 clinical trial demonstrated the potential clinical benefit mediated by the infused T cell product, which allows the patient’s own immune system to participate in the anti-tumor effect.1

1Biology of Blood Marrow Transplantation, 23 (2017) S18–S391. DOI: 10.1016/j.bbmt.2016.12.100